Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Trial Profile

Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2016

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Haemangiosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Apr 2014 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University).
    • 17 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 10 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top